Boehringer Files Pradaxa Antidote, Could Be First Reversible Novel Anticoagulant

Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.